Novel Protein Degraders May Revolutionize Immune Condition Treatment
Executive Brief
- The News: Novartis pays $120 million upfront to Monte Rosa.
- Clinical Win: Potential to access tough-to-reach drug targets with "molecular glue" drugs.
- Target Specialty: Immunologists treating immune-mediated diseases with high unmet need.
Key Data at a Glance
Upfront Cash: $120 million
Total Potential Payment: $5.7 billion
Stock Price Increase: 50%
Initial Public Offering: $222 million
Targeted Approach: Molecular glue drugs
Development Stage: Phase 2 testing
Novel Protein Degraders May Revolutionize Immune Condition Treatment
Novartis is broadening its bet on drugs that can destroy disease-causing proteins, agreeing Monday to a new deal with biotechnology company Monte Rosa Therapeutics.
Through the collaboration, the companies will work to develop multiple novel protein “degrading” drugs for immune conditions. Monte Rosa will conduct discovery and early testing before Novartis takes over development for programs it chooses to license. The biotech will get $120 million in upfront cash per deal terms. It could also receive as much as $5.7 billion overall should various development and sales milestones be met, plus royalties on sales of any eventual products.
Monte Rosa shares climbed by about 50% in pre-market trading. At about $7.30 apiece, however, the company’s stock trades well below its debut price following a $222 million initial public offering in 2021.
Monte Rosa is among the many companies pursuing “molecular glue” drugs, which force together a target protein with an enzyme that flags it for destruction by the cell’s waste disposal system. The approach is seen as a way to access tough-to-reach drug targets, and is one of several strategies biotechs are using to degrade harmful proteins, rather than bind and block them as traditional drugs do.
Novartis has been particularly active pursuing deals focused on protein degradation. In 2020, it formed a discovery alliance with Orionis Biosciences that involved degrader research. And last year, it licensed a prostate cancer drug from Arvinas as well as an experimental immune disease medicine from Monte Rosa. Both of those drugs are either in or nearing Phase 2 testing.
The new collaboration with Monte Rosa is broader, handing Novartis rights to a therapy aimed at an undisclosed target as well as options to license two programs from the company’s stockpile of preclinical immune disease drug candidates.
The agreement “underscores our commitment to advancing targeted protein degradation as a promising approach to address immune-mediated diseases with high unmet need,” said Fiona Marshall, head of biomedical research at Novartis, in a statement. Marshall added that Monte Rosa’s drug discovery technology “has the potential to uncover new insights into this field.”
Monte Rosa CEO Markus Warmuth noted, in the statement, how the deal gives his company enough financial breathing room to reach Phase 2 readouts for multiple programs, among them MRT-6160, the drug in the original Novartis deal.
Clinical Perspective — Dr. Shruti Pandey, Hematology
Workflow: As I manage patients with immune conditions, I'm interested in the development of protein degraders, which could potentially offer new treatment options. The collaboration between Novartis and Monte Rosa Therapeutics to develop multiple novel protein "degrading" drugs may lead to new therapies, but it's too early to say how this will change my daily routine. I'll be watching for updates on the progress of these programs.
Economics: The article doesn't address cost directly, but the deal terms suggest that Novartis is investing heavily in protein degradation research, with Monte Rosa receiving $120 million in upfront cash and potentially up to $5.7 billion overall. This significant investment may lead to new treatment options, but the cost impact on healthcare systems and patients remains to be seen.
Patient Outcomes: The potential for protein degraders to target "tough-to-reach" drug targets could lead to significant benefits for patients with immune conditions. While it's too early to quantify the potential benefits, the approach of using "molecular glue" drugs to force together a target protein with an enzyme that flags it for destruction may offer new hope for patients with limited treatment options, such as those with prostate cancer, where Novartis has licensed a drug from Arvinas that is either in or nearing Phase 2 testing.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].